Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

p38γ is essential for cell cycle progression and liver tumorigenesis.

  • Tomas-Loba, Antonia
  • Manieri, Elisa
  • Gonzalez-Teran, Barbara
  • Mora, Alfonso
  • Leiva-Vega, Luis
  • Santamans, Ayelen M
  • Romero-Becerra, Rafael
  • Rodríguez, Elena
  • Pintor-Chocano, Aránzazu
  • Feixas, Ferran
  • Lopez, Juan Antonio
  • Caballero, Beatriz
  • Trakala, Marianna
  • Blanco, Óscar
  • Torres, Jorge L
  • Hernández-Cosido, Lourdes
  • Montalvo-Romeral, Valle
  • Matesanz, Nuria
  • Roche-Molina, Marta
  • Bernal, Juan Antonio
  • Mischo, Hannah
  • León, Marta
  • Caballero, Ainoa
  • Miranda-Saavedra, Diego
  • Ruiz-Cabello, Jesus
  • Nevzorova, Yulia A
  • Cubero, Francisco Javier
  • Bravo, Jerónimo
  • Vazquez, Jesus
  • Malumbres, Marcos
  • Marcos, Miguel
  • Osuna, Sílvia
  • Sabio, Guadalupe
The cell cycle is a tightly regulated process that is controlled by the conserved cyclin-dependent kinase (CDK)-cyclin protein complex1. However, control of the G0-to-G1 transition is not completely understood. Here we demonstrate that p38 MAPK gamma (p38γ) acts as a CDK-like kinase and thus cooperates with CDKs, regulating entry into the cell cycle. p38γ shares high sequence homology, inhibition sensitivity and substrate specificity with CDK family members. In mouse hepatocytes, p38γ induces proliferation after partial hepatectomy by promoting the phosphorylation of retinoblastoma tumour suppressor protein at known CDK target residues. Lack of p38γ or treatment with the p38γ inhibitor pirfenidone protects against the chemically induced formation of liver tumours. Furthermore, biopsies of human hepatocellular carcinoma show high expression of p38γ, suggesting that p38γ could be a therapeutic target in the treatment of this disease.
Repisalud
Publication Artículo científico (JournalArticle)

Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis

  • Porteiro, Begona
  • Fondevila, Marcos F.
  • Buque, Xabier
  • Gonzalez-Rellan, Maria J.
  • Fernandez, Uxia
  • Mora, Alfonso
  • Beiroa, Daniel
  • Senra, Ana
  • Gallego, Rosalia
  • Ferno, Johan
  • Lopez, Miguel
  • Sabio, Guadalupe
  • Dieguez, Carlos
  • Aspichueta, Patricia
  • Nogueiras, Ruben
Objective: Recent reports have implicated the p53 tumor suppressor in the regulation of lipid metabolism. We hypothesized that the pharmacological activation of p53 with low-dose doxorubicin, which is widely used to treat several types of cancer, may have beneficial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Methods: We used long-term pharmacological activation of p53 by i.p. or oral administration of low-dose doxorubicin in different animal models of NAFLD (high fat diet containing 45\% and 60\% kcal fat) and NASH (methionine- and choline-deficient diet and choline deficiency combined with high fat diet). We also administered doxorubicin in mice lacking p53 in the liver and in two human hepatic cells lines (HepG2 and THLE2). Results: The attenuation of liver damage was accompanied by the stimulation of fatty acid oxidation and decrease of lipogenesis, inflammation, and ER stress. The effects of doxorubicin were abrogated in mice with liver-specific ablation of p53. Finally, the effects of doxorubicin on lipid metabolism found in animal models were also present in two human hepatic cells lines, in which the drug stimulated fatty acid oxidation and inhibited de novo lipogenesis at doses that did not cause changes in apoptosis or cell viability. Conclusion: These data provide new evidence for targeting p53 as a strategy to treat liver disease. (C) 2017 The Authors. Published by Elsevier GmbH.
Repisalud
Publication Artículo científico (JournalArticle)

Hepatic p63 regulates steatosis via IKK beta/ER stress

  • Porteiro, Begona
  • Fondevila, Marcos F.
  • Delgado, Teresa C.
  • Iglesias, Cristina
  • Imbernon, Monica
  • Iruzubieta, Paula
  • Crespo, Javier
  • Zabala-Letona, Amaia
  • Ferno, Johan
  • Gonzalez-Teran, Barbara
  • Matesanz, Nuria
  • Hernandez-Cosido, Lourdes
  • Marcos, Miguel
  • Tovar, Sulay
  • Vidal, Anxo
  • Sanchez-Ceinos, Julia
  • Malagon, Maria M.
  • Pombo, Celia
  • Zalvide, Juan
  • Carracedo, Arkaitz
  • Buque, Xabier
  • Dieguez, Carlos
  • Sabio, Guadalupe
  • Lopez, Miguel
  • Aspichueta, Patricia
  • Martinez-Chantar, Maria L.
  • Nogueiras, Ruben
p53 family members control several metabolic and cellular functions. The p53 ortholog p63 modulates cellular adaptations to stress and has a major role in cell maintenance and proliferation. Here we show that p63 regulates hepatic lipid metabolism. Mice with liver-specific p53 deletion develop steatosis and show increased levels of p63. Down-regulation of p63 attenuates liver steatosis in p53 knockout mice and in diet-induced obese mice, whereas the activation of p63 induces lipid accumulation. Hepatic overexpression of N-terminal transactivation domain TAp63 induces liver steatosis through IKK beta activation and the induction of ER stress, the inhibition of which rescues the liver functions. Expression of TAp63, IKK beta and XBP1s is also increased in livers of obese patients with NAFLD. In cultured human hepatocytes, TAp63 inhibition protects against oleic acid-induced lipid accumulation, whereas TAp63 overexpression promotes lipid storage, an effect reversible by IKK beta silencing. Our findings indicate an unexpected role of the p63/IKK beta/ER stress pathway in lipid metabolism and liver disease.
Repisalud
Publication Artículo científico (JournalArticle)

Adiponectin accounts for gender differences in hepatocellular carcinoma incidence

  • Manieri, Elisa
  • Herrera-Melle, Leticia
  • Mora, Alfonso
  • Tomas-Loba, Antonia
  • Leiva-Vega, Luis
  • Fernandez, Delia I
  • Rodriguez, Elena
  • Morán, Laura
  • Hernández-Cosido, Lourdes
  • Torres, Jorge L
  • Seoane, Luisa M
  • Cubero, Francisco Javier
  • Marcos, Miguel
  • Sabio, Guadalupe
Hepatocellular carcinoma (HCC) is the sixth most common cancer type and the fourth leading cause of cancer-related death. This cancer appears with higher incidence in men and during obesity; however, the specific mechanisms underlying this correlation are unknown. Adipose tissue, a key organ in metabolic syndrome, shows evident gender disparities in the production of adipokines. Levels of the important adipokine adiponectin decrease in men during puberty, as well as in the obese state. Here, we show that this decrease in adiponectin levels is responsible for the increased liver cancer risk in males. We found that testosterone activates the protein JNK in mouse and human adipocytes. JNK-mediated inhibition of adiponectin secretion increases liver cancer cell proliferation, since adiponectin protects against liver cancer development through the activation of AMP-activated protein kinase (AMPK) and p38α. This study provides insight into adipose tissue to liver crosstalk and its gender relation during cancer development, having the potential to guide strategies for new cancer therapeutics.
Repisalud
Publication Artículo científico (JournalArticle)

p38 MAPK Pathway in the Heart: New Insights in Health and Disease.

  • Romero-Becerra, Rafael
  • Santamans, Ayelen M
  • Folgueira, Cintia
  • Sabio, Guadalupe
The p38 mitogen-activated kinase (MAPK) family controls cell adaptation to stress stimuli. p38 function has been studied in depth in relation to cardiac development and function. The first isoform demonstrated to play an important role in cardiac development was p38α; however, all p38 family members are now known to collaborate in different aspects of cardiomyocyte differentiation and growth. p38 family members have been proposed to have protective and deleterious actions in the stressed myocardium, with the outcome of their action in part dependent on the model system under study and the identity of the activated p38 family member. Most studies to date have been performed with inhibitors that are not isoform-specific, and, consequently, knowledge remains very limited about how the different p38s control cardiac physiology and respond to cardiac stress. In this review, we summarize the current understanding of the role of the p38 pathway in cardiac physiology and discuss recent advances in the field.
Repisalud
Publication Artículo científico (JournalArticle)

MKK6 controls T3-mediated browning of white adipose tissue

  • Matesanz, Nuria
  • Bernardo, Edgar
  • Acin-Perez, Rebeca
  • Manieri, Elisa
  • Perez-Sieira, Sonia
  • Hernandez-Cosido, Lourdes
  • Montalvo-Romeral, Valle
  • Mora, Alfonso
  • Rodriguez, Elena
  • Leiva-Vega, Luis
  • Lechuga-Vieco, Ana V.
  • Ruiz-Cabello, Jesus
  • Torres, Jorge L
  • Crespo-Ruiz, Maria
  • Centeno, Francisco
  • Alvarez, Clara V.
  • Marcos, Miguel
  • Enriquez, Jose Antonio
  • Nogueiras, Ruben
  • Sabio, Guadalupe
Increasing the thermogenic capacity of adipose tissue to enhance organismal energy expenditure is considered a promising therapeutic strategy to combat obesity. Here, we report that expression of the p38 MAPK activator MKK6 is elevated in white adipose tissue of obese individuals. Using knockout animals and shRNA, we show that Mkk6 deletion increases energy expenditure and thermogenic capacity of white adipose tissue, protecting mice against diet-induced obesity and the development of diabetes. Deletion of Mkk6 increases T3-stimulated UCP1 expression in adipocytes, thereby increasing their thermogenic capacity. Mechanistically, we demonstrate that, in white adipose tissue, p38 is activated by an alternative pathway involving AMPK, TAK, and TAB. Our results identify MKK6 in adipocytes as a potential therapeutic target to reduce obesity.
Repisalud
Publication Artículo científico (JournalArticle)

p38α blocks brown adipose tissue thermogenesis through p38δ inhibition

  • Matesanz, Nuria
  • Nikolic, Ivana
  • Leiva, Magdalena
  • Pulgarin-Alfaro, Marta
  • Santamans, Ayelen M
  • Bernardo, Edgar
  • Mora, Alfonso
  • Herrera-Melle, Leticia
  • Rodriguez, Elena
  • Beiroa, Daniel
  • Caballero, Ainoa
  • Martin-Garcia, Elena
  • Acin-Perez, Rebeca
  • Hernández-Cosido, Lourdes
  • Leiva-Vega, Luis
  • Torres, Jorge L
  • Centeno, Francisco
  • Nebreda, Angel R
  • Enriquez, Jose Antonio
  • Nogueiras, Rubén
  • Marcos, Miguel
  • Sabio, Guadalupe
Adipose tissue has emerged as an important regulator of whole-body metabolism, and its capacity to dissipate energy in the form of heat has acquired a special relevance in recent years as potential treatment for obesity. In this context, the p38MAPK pathway has arisen as a key player in the thermogenic program because it is required for the activation of brown adipose tissue (BAT) thermogenesis and participates also in the transformation of white adipose tissue (WAT) into BAT-like depot called beige/brite tissue. Here, using mice that are deficient in p38α specifically in adipose tissue (p38αFab-KO), we unexpectedly found that lack of p38α protected against high-fat diet (HFD)-induced obesity. We also showed that p38αFab-KO mice presented higher energy expenditure due to increased BAT thermogenesis. Mechanistically, we found that lack of p38α resulted in the activation of the related protein kinase family member p38δ. Our results showed that p38δ is activated in BAT by cold exposure, and lack of this kinase specifically in adipose tissue (p38δ Fab-KO) resulted in overweight together with reduced energy expenditure and lower body and skin surface temperature in the BAT region. These observations indicate that p38α probably blocks BAT thermogenesis through p38δ inhibition. Consistent with the results obtained in animals, p38α was reduced in visceral and subcutaneous adipose tissue of subjects with obesity and was inversely correlated with body mass index (BMI). Altogether, we have elucidated a mechanism implicated in physiological BAT activation that has potential clinical implications for the treatment of obesity and related diseases such as diabetes.
Repisalud
Publication Artículo científico (JournalArticle)

JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma.

  • Manieri, Elisa
  • Folgueira, Cintia
  • Rodríguez, María Elena
  • Leiva-Vega, Luis
  • Esteban-Lafuente, Laura
  • Chen, Chaobo
  • Cubero, Francisco Javier
  • Barrett, Tamera
  • Cavanagh-Kyros, Julie
  • Seruggia, Davide
  • Rosell, Alejandro
  • Sanchez-Cabo, Fatima
  • Gomez, Manuel J
  • Monte, Maria J
  • G Marin, Jose J
  • Davis, Roger J
  • Mora, Alfonso
  • Sabio, Guadalupe
Metabolic stress causes activation of the cJun NH2-terminal kinase (JNK) signal transduction pathway. It is established that one consequence of JNK activation is the development of insulin resistance and hepatic steatosis through inhibition of the transcription factor PPARα. Indeed, JNK1/2 deficiency in hepatocytes protects against the development of steatosis, suggesting that JNK inhibition represents a possible treatment for this disease. However, the long-term consequences of JNK inhibition have not been evaluated. Here we demonstrate that hepatic JNK controls bile acid production. We found that hepatic JNK deficiency alters cholesterol metabolism and bile acid synthesis, conjugation, and transport, resulting in cholestasis, increased cholangiocyte proliferation, and intrahepatic cholangiocarcinoma. Gene ablation studies confirmed that PPARα mediated these effects of JNK in hepatocytes. This analysis highlights potential consequences of long-term use of JNK inhibitors for the treatment of metabolic syndrome.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Eukaryotic elongation factor 2 controls TNF-α translation in LPS-induced hepatitis

  • Manieri, Elisa
  • Verdugo, Ángeles
  • González-Rodríguez, Águeda
  • Valverde, Ángela M.
  • Sabio, Guadalupe
15 páginas, 7 figuras.-- et al., Bacterial LPS (endotoxin) has been implicated in the pathogenesis of acute liver disease through its induction of the proinflammatory cytokine TNF-α. TNF-α is a key determinant of the outcome in a well-established mouse model of acute liver failure during septic shock. One possible mechanism for regulating TNF-α expression is through the control of protein elongation during translation, which would allow rapid cell adaptation to physiological changes. However, the regulation of translational elongation is poorly understood. We found that expression of p38γ/δMAPK proteins is required for the elongation of nascent TNF-α protein in macrophages. The MKK3/6-p38γ/δpathway mediated an inhibitory phosphorylation of eukaryotic elongation factor 2 (eEF2) kinase, which in turn promoted eEF2 activation (dephosphorylation) and subsequent TNF-α elongation. These results identify a new signaling pathway that regulates TNF-α production in LPS-induced liver damage and suggest potential cell-specific therapeutic targets for liver diseases in which TNF-α production is involved., G. Sabio is an investigator of the Ramón y Cajal Program and a recipient of a Principe de Girona Impulsa award. R.J. Davis is an investigator of the Howard Hughes Medical Institute. Á. Verdugo is a recipient of a Madrid Regional Government fellowship. E. Manieri is a fellow of the La Caixa Foundation Á. González-Rodríguez was supported by CIBERDEM (ISCIII, Spain). This work was funded by the following grants: ERC 260464, EFSD 2030, MICINN SAF2010-19347, and Comunidad de Madrid S2010/BMD-2326 (to G. Sabio:); MICINN SAF2011-27330 (to P. Martin); and MICINN SAF2012-3328 (to Á. Valverde). The CNIC is supported by the Ministry of Economy and Competitiveness and the Pro-CNIC Foundation., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

p38γ is essential for cell cycle progression and liver tumorigenesis

  • Tomás-Loba, Antonia
  • Manieri, Elisa
  • González-Terán, Bárbara
  • Mora, Alfonso
  • Leiva-Vega, Luis
  • Santamans, Ayelén M.
  • Romero-Becerra, Rafael
  • Rodríguez, Elena
  • Pintor-Chocano, Aránzazu
  • Feixas, Ferran
  • López, Juan Antonio
  • Caballero, Beatriz
  • Trakala, Marianna
  • Blanco, Óscar
  • Torres, Jorge L.
  • Hernández-Cosido, Lourdes
  • Montalvo-Romeral, Valle
  • Matesanz, Nuria
  • Roche-Molina, Marta
  • Bernal, Juan Antonio
  • Mischo, Hannah
  • León, Marta
  • Caballero, Ainoa
  • Miranda-Saavedra, Diego
  • Ruiz-Cabello, Jesús
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Bravo, Jerónimo
  • Vázquez, Jesús
  • Malumbres, Marcos
  • Marcos, Miguel
  • Osuna, Sílvia
  • Sabio, Guadalupe
27 páginas, 4 figuras. Contiene material suplementario, método, 6 figuras en: https://doi.org/10.1038/s41586-019-1112-8, The cell cycle is a tightly regulated process that is controlled by the conserved cyclin-dependent kinase (CDK)-cyclin protein complex1. However, control of the G0-to-G1 transition is not completely understood. Here we demonstrate that p38 MAPK gamma (p38γ) acts as a CDK-like kinase and thus cooperates with CDKs, regulating entry into the cell cycle. p38γ shares high sequence homology, inhibition sensitivity and substrate specificity with CDK family members. In mouse hepatocytes, p38γ induces proliferation after partial hepatectomy by promoting the phosphorylation of retinoblastoma tumour suppressor protein at known CDK target residues. Lack of p38γ or treatment with the p38γ inhibitor pirfenidone protects against the chemically induced formation of liver tumours. Furthermore, biopsies of human hepatocellular carcinoma show high expression of p38γ, suggesting that p38γ could be a therapeutic target in the treatment of this disease, s We thank S. Bartlett for English editing, D. Engelberg for the constitutively active mutants, the Division of Signal Transduction Therapy for recombinant proteins, and CNIC Advanced Imaging and Vector Units for technical support. G.S. (RYC-2009-04972), F.J.C. (RYC-2014-15242), and Y.A.N. (RYC-2015-17438) are investigators of the Ramón y Cajal Program. E.M. and M.T. were awarded La Caixa fellowships and R.R.-B. was a fellow of the Fundación Ramón Areces-UAM and FPU. B.G.-T. is a fellow of the FPI Severo Ochoa CNIC program (SVP-2013-067639). F.J.C. is a Gilead Liver Research Scholar. This work was funded by grants supported in part by funds from the European Regional Development Fund: the European Union’s Seventh Framework Programme (FP7/2007-2013) ERC 260464, EFSD/Lilly European Diabetes Research Programme Dr Sabio, 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation (InvestigadoresBBVA-2017) IN[17]_BBM_BAS_0066, MINECO-FEDER SAF2016-79126-R, and Comunidad de Madrid IMMUNOTHERCAN-CM S2010/BMD-2326 and B2017/ BMD-3733 to G.S.; Juan de la Cierva and MINECO SAF2014-61233-JIN to A.T.-L.; the European Community for MSCA-IF-2014-EF-661160-MetAccembly grant to F.F.; Spanish MINECO CTQ2014-59212-P, European Community for CIG project (PCIG14-GA-2013-630978), and European Research Council (ERC) under the European Union’s Horizon 2020 (ERC-2015-StG-679001- NetMoDEzyme) to S.O.; the German Research Foundation (SFB/TRR57/P04 and DFG NE 2128/2-1) and MINECO SAF2017-87919R to Y.A.N.; EXOHEP-CM S2017/BMD-3727 and the COST Action CA17112, MINECO SAF2016-78711, and the AMMF Cholangiocarcinoma Charity 2018/117 to F.J.C.; MINECO (SAF2015-69920-R co-funded by ERDF-EU), the Consolider-Ingenio 2010 Programme (SAF2014-57791-REDC), Excellence Network CellSYS (BFU2014- 52125-REDT), and the iLUNG Programme (B2017/BMD-3884) from the Comunidad de Madrid to M. Malumbres; MINECO SAF2015-67077-R and SAF2017-89901-R to J.B.; MINECO (BIO2015-67580-P), Carlos III Institute of Health-Fondo de Investigación Sanitaria (ProteoRed PRB3, IPT17/0019 - ISCIII-SGEFI/ERDF), Fundación La Marató and ‘La Caixa’ Banking Foundation (HR17-00247) to J.V.; ISCIII and FEDER PI16/01548 and Junta de Castilla y León GRS 1362/A/16 and INT/M/17/17 to M. Marcos; Junta de Castilla y León GRS 1356/A/16 and GRS 1587/A/17 to J.L.-T.; and MCNU (SAF2017- 84494-C2-1-R) to J.R.-C. The CNIC is supported by the Ministerio de Ciencia, Innovación y Universidades (MCNU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma

  • Manieri, Elisa
  • Folgueira, Cintia
  • Rodríguez, María Elena
  • Leiva-Vega, Luis
  • Esteban-Lafuente, Laura
  • Chen, Chaobo
  • Cubero, Francisco Javier
  • Barrett, Tamera
  • Cavanagh-Kyros, Julie
  • Seruggia, Davide
  • Rosell, Alejandro
  • Sánchez-Cabo, Fátima
  • Gómez, Manuel José
  • Monte, Maria J.
  • Marín, José J. G.
  • Davis, Roger J.
  • Mora, Alfonso
  • Sabio, Guadalupe
Metabolic stress causes activation of the cJun NH2-terminal kinase (JNK) signal transduction pathway. It is established that one consequence of JNK activation is the development of insulin resistance and hepatic steatosis through inhibition of the transcription factor PPARα. Indeed, JNK1/2 deficiency in hepatocytes protects against the development of steatosis, suggesting that JNK inhibition represents a possible treatment for this disease. However, the long-term consequences of JNK inhibition have not been evaluated. Here we demonstrate that hepatic JNK controls bile acid production. We found that hepatic JNK deficiency alters cholesterol metabolism and bile acid synthesis, conjugation, and transport, resulting in cholestasis, increased cholangiocyte proliferation, and intrahepatic cholangiocarcinoma. Gene ablation studies confirmed that PPARα mediated these effects of JNK in hepatocytes. This analysis highlights potential consequences of long-term use of JNK inhibitors for the treatment of metabolic syndrome., We are grateful to the CNIC Advanced Imaging and Animal facility for technical support. G.S. (RYC-2009-04972) and F.J.C. (RYC-2014-15242) are investigators of the Ramón y Cajal Program. E.M. was awarded a La Caixa fellowship. C.F. was awarded a Sara Borrell contract (CD19/00078). This work was funded by grants supported in part by funds from the European Regional Development Fund: EU’s Seventh Framework Programme (FP7/2007-2013) ERC 260464, EFSD/Lilly European Diabetes Research Programme Dr. Sabio, 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation (Investigadores-BBVA-2017) IN[17]_BBM_BAS_0066, MINECO-FEDER SAF2016-79126-R, and Comunidad de Madrid IMMUNOTHERCAN-CM S2010/BMD-2326 and B2017/BMD-3733 and La Asociación Española contra el Cáncer (to G.S.); EXOHEP-CM S2017/BMD-3727 and the European Cooperation in Science & Technology (COST) Action CA17112 (to F.J.C.); MINECO Retos SAF2016-78711, the AMMF Cholangiocarcinoma Charity 2018/117, NanoLiver-CM Y2018/NMT-4949, UCM-25-2019, ERAB EA/18-14 (to F.J.C.). F.J.C. is a Gilead Liver Research Scholar. Grant DK R01 DK107220 from the NIH (to R.J.D.); and PI16/00598 from Carlos III Institute of Health, Spain (to J.J.G.M.). The CNIC is supported by the Ministerio de Ciencia, Innovación y Universidades, and the Pro-CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Hypothalamic AMPK-ER Stress-JNK1 axis mediates the central actions of thyroid hormones on energy balance

  • Martinez-Sanchez, Noelia
  • Seoane-Collazo, Patricia
  • Contreras, Cristina
  • Varela, Luis
  • Villarroya, Joan
  • Rial-Pensado, Eva
  • Buque, Xabier
  • Aurrekoetxea, Igor
  • Delgado, Teresa C.
  • Vazquez-Martinez, Rafael
  • Gonzalez-Garcia, Ismael
  • Roa, Juan
  • Whittle, Andrew J.
  • Gomez-Santos, Beatriz
  • Velagapudi, Vidya
  • Loraine Tung, Y. C.
  • Morgan, Donald A.
  • Voshol, Peter J.
  • Martinez de Morentin, Pablo B.
  • Lopez-Gonzalez, Tania
  • Linares-Pose, Laura
  • Gonzalez, Francisco
  • Chatterjee, Krishna
  • Sobrino, Tomas
  • Medina-Gomez, Gema
  • Davis, Roger J.
  • Casals i Farré, Núria
  • Oresic, Matej
  • Coll, Anthony P.
  • Vidal-Puig, Antonio
  • Mittag, Jens
  • Tena-Sempere, Manuel
  • Malagon, Maria M.
  • Dieguez, Carlos
  • Martinez-Chantar, Maria Luz
  • Aspichueta, Patricia
  • Rahmouni, Kamal
  • Nogueiras, Rubén
  • Sabio, Guadalupe
  • Villarroya, Francesc
  • Lopez, Miguel
We dedicate this work to the bright memory of our colleague and friend Rafael Vazquez-Martınez. The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreements n260464 – the OBECAN project (G.S.) and n 281854 – the ObERStress project (M.L.), Xunta de Galicia (F.G., ED431C2016-025 and ED341D-R2016-032; R.N., 2015-CP080 and 2016-PG057; M.L., 2015-CP079 and 2016-PG068), Junta de Andalucı´a (M.T.-S., P12-FQM-01943), Gobierno Vasco-Departamento de Salud (M.L.M.-C., 2013111114), EITB (M.L.M.-C., BIO15/CA/014), Ayudas para apoyar grupos de investigacion del sistema Universitario Vasco (P.A., IT971-16), Generalitat de Catalunya (N.C., 2014SGR465), Fundacio´ La Marato´ de TV3 (N.C., 87/C/2016), Instituto de Salud Carlos III co-funded by FEDER (F.G., RD16/0008/0003; M.L.M.-C., PIE14/00031), Ministerio de Economı´a y Competitividad (MINECO) co-funded by the FEDER Program of EU (N.C., SAF2014-52223-C2-2-R; M.T.-S., BFU2014-57581-P -P; M.M.M., BFU2013-44229-R; C.D., BFU2014-55871-P; M.L.M.-C., SAF2014-54658-R; P.A., SAF2015-64352-R; R.N., BFU2015-70664R; G.S., SAF2013-43506-R; F.V., SAF2014 55725; M.L., SAF2015-71026-R; G.M., M.M.M., F.V., and M.L., BFU2015-70454-REDT/Adipoplast), Asociacio´ n Espan˜ ola contra el Ca´ ncer (T.C.D. and M.L.M.-C.), Medical Research Council (MRC) Metabolic Diseases Unit (A.J.W., Y.C.L.T., A.P.C., and A.V.-P., MRC_MC_UU_12012/1 and MRC_UU_12015/5), MRC Programme Grant (Y.C.L.T. and A.P.C., G9824984), MRC Disease Model Core (P.J.V. and A.V.-P.), Wellcome Trust Investigator Award (K.C., 095564/Z/11/Z), Deutsche Forschungsgemeinschaft (J.M., Mi1242/2-1), NIH (R.J.D., DK107220 and DK112698; K.R., HL084207), American Heart Association (K.R., EIA#14EIA18860041) and the University of Iowa Fraternal Order of Eagles Diabetes Research Center (K.R.), EFSD/Lilly Programme (G.S., GIM/EFS1601), Astra Zeneca Foundation (R.N.) and the European Foundation for the Study of Diabetes (R.N.), and Atresmedia Corporacion (M.L.). C.C. is recipient of a Sara Borrell Contract (CD14/0007) from ISCIII; J.V. is recipient of a Juan de la Cierva Contract (IJDC-2014-19681) from MINECO; E.R.-P. is recipient of a fellowship from MINECO (BES-2015-072743); I.G.-G. is recipient of a fellowship from MINECO (FPU12/01827); L.L.-P. is recipient of a fellowship from Xunta de Galicia (ED481A-2016/094); T.C.D. is supported by AECC (AIO2013); T.S. is recipient of a Miguel Servet Contract (CP12/03121) from ISCIII; R.J.D. is an Investigator of the Howard Hughes Medical Institute; and F.V. is an ICREA Academia researcher, Generalitat de Catalunya. The CiMUS is supported by the Xunta de Galicia (2016–2019, ED431G/05) and the CNIC is supported by the MINECO and the Pro-CNIC Foundation. Pro-CNIC Foundation is a Severo Ochoa Center of Excellence (MINECO award SEV2015-0505). The technical assistance of Luz Casas in performing the in situ hybridization, Maria Jesus Sanchez-Tapia in performing genotyping analyses, and Tuulikki Seppanen-Laakso and Ulla Lahtinen in performing lipidomics ana- €lyses is cordially appreciated. CIBER de Fisiopatologı´a de la Obesidad y Nutricio´ n and CIBER de Enfermedades hepa´ticas y Digestivas are initiatives of ISCIII. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Thyroid hormones (THs) act in the brain to modulate energy balance. We show that central triiodothyronine (T3) regulates de novo lipogenesis in liver and lipid oxidation in brown adipose tissue (BAT) through the parasympathetic (PSNS) and sympathetic nervous system (SNS), respectively. Central T3 promotes hepatic lipogenesis with parallel stimulation of the thermogenic program in BAT. The action of T3 depends on AMP-activated protein kinase (AMPK)-induced regulation of two signaling pathways in the ventromedial nucleus of the hypothalamus (VMH): decreased ceramide-induced endoplasmic reticulum(ER) stress, which promotes BAT thermogenesis, and increased c-Jun N-terminal kinase (JNK) activation, which controls hepatic lipid metabolism. Of note, ablation of AMPK alpha 1 in steroidogenic factor 1 (SF1) neurons of the VMH fully recapitulated the effect of central T3, pointing to this population in mediating the effect of central THs on metabolism. Overall, these findings uncover the underlying pathways through which central T3 modulates peripheral metabolism., info:eu-repo/semantics/acceptedVersion